The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Citation
Eslam, M., Fan, J. G., Yu, M. L., Wong, V. W., Cua, I. H., Liu, C. J., Tanwandee, T., Gani, R., Seto, W. K., Alam, S., Young, D. Y., Hamid, S., Zheng, M. H., Kawaguchi, T., Chan, W. K., Payawal, D., Tan, S. S., Goh, G. B., Strasser, S. I., Viet, H. D., … George, J. (2025). The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatology international, 19(2), 261–301. https://doi.org/10.1007/s12072-024-10774-3Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for the Study of the Liver (APASL) has created clinical practice guidelines focused on MAFLD. The guidelines cover various aspects of the disease, such as its epidemiology, diagnosis, screening, assessment, and treatment. The guidelines aim to advance clinical practice, knowledge, and research on MAFLD, particularly in special groups. The guidelines are designed to advance clinical practice, to provide evidence-based recommendations to assist healthcare stakeholders in decision-making and to improve patient care and disease awareness. The guidelines take into account the burden of clinical management for the healthcare sector.
